Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014 (2014), Article ID 949515, 4 pages
http://dx.doi.org/10.1155/2014/949515
Case Report

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide

Bagi Jana,1,2,3 Anas Khanfar,1,2 and Mary Ninan1,2,3

1The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
2Department of Internal Medicine, 301 University Boulevard, Galveston, TX 77555, USA
3Divisions of Hematology and Oncology, 301 University Boulevard, Galveston, TX 77555, USA

Received 10 December 2013; Accepted 31 December 2013; Published 12 February 2014

Academic Editors: K. Jamil and D. Yin

Copyright © 2014 Bagi Jana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Fenaux, “Myelodysplastic syndromes: from pathogenesis and prognosis to treatment,” Seminars in Hematology, vol. 41, no. 2, pp. 6–12, 2004. View at Google Scholar · View at Scopus
  2. A. J. Bench, E. P. Nacheva, T. L. Hood et al., “Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes,” Oncogene, vol. 19, no. 34, pp. 3902–3913, 2000. View at Google Scholar · View at Scopus
  3. R. Gupta, C. P. Soupir, V. Johari, and R. P. Hasserjian, “Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation,” British Journal of Haematology, vol. 139, no. 2, pp. 265–268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Haase, U. Germing, J. Schanz et al., “New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients,” Blood, vol. 110, no. 13, pp. 4385–4395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. W.-K. Hofmann, M. Lübbert, D. Hoelzer, and H. P. Koeffler, “Myelodysplastic syndromes,” Hematology Journal, vol. 5, no. 1, pp. 1–8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Huh, R. V. Tiu, L. P. Gondek et al., “Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis,” Genes Chromosomes and Cancer, vol. 49, no. 4, pp. 390–399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Greenberg, C. Cox, M. M. LeBeau et al., “International scoring system for evaluating prognosis in myelodysplastic syndromes,” Blood, vol. 89, no. 6, pp. 2079–2088, 1997. View at Google Scholar · View at Scopus
  8. T. Braun, S. de Botton, A.-L. Taksin et al., “Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases,” Leukemia Research, vol. 35, no. 7, pp. 863–867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. B. Bartlett, K. Dredge, and A. G. Dalgleish, “The evolution of thalidomide and its IMiD derivatives as anticancer agents,” Nature Reviews Cancer, vol. 4, no. 4, pp. 314–322, 2004. View at Google Scholar · View at Scopus
  10. R. Knight, “IMiDs: a novel class of immunomodulators,” Seminars in Oncology, vol. 32, no. 5, pp. S24–S30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. List, G. Dewald, J. Bennett et al., “Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1456–1465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Raza, J. A. Reeves, E. J. Feldman et al., “Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q,” Blood, vol. 111, no. 1, pp. 86–93, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Xu, X. Li, C. Chang et al., “A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q),” Leukemia Research, vol. 33, no. 11, pp. e199–e202, 2009. View at Publisher · View at Google Scholar · View at Scopus